OBJECTIVE: To determine the patterns of aspirin use for the primary prevention of coronary heart disease (CHD). Aspirin for primary prevention has a more favorable risk/benefit profile among adults with high CHD risk than among low-risk adults. METHOD: We studied 5725 adults aged 35-75 without cardiovascular disease in a population-based study in Switzerland in 2003-2006. We examined regular aspirin use for cardiovascular prevention according to 10-year CHD risk and other cardiovascular risk factors. RESULTS: One hundred seventy-four participants used aspirin. Aspirin use increased with 10-year CHD risk, from 2.6% in persons with risk <6% (low risk) to 9% in those with risk 6-20% (intermediate risk, p=0.001), but no adults with risk >or=20% used aspirin. Participants with cardiovascular risk factors were more likely to use aspirin. However, 1.9% adults with risk <6% and no diabetes used aspirin. Using a population perspective, a more appropriate aspirin use would reduce up to 2,348/24,310 CHD deaths expected over 10 years in Switzerland, and avoid about 700 gastrointestinal bleedings and hemorrhagic strokes among those not eligible. CONCLUSION: Individuals at intermediate CHD risk and diabetics are more likely to take aspirin, but there are significant opportunities for improvement. The underuse of aspirin for those at risk coexists with an overuse among those at low risk.
OBJECTIVE: To determine the patterns of aspirin use for the primary prevention of coronary heart disease (CHD). Aspirin for primary prevention has a more favorable risk/benefit profile among adults with high CHD risk than among low-risk adults. METHOD: We studied 5725 adults aged 35-75 without cardiovascular disease in a population-based study in Switzerland in 2003-2006. We examined regular aspirin use for cardiovascular prevention according to 10-year CHD risk and other cardiovascular risk factors. RESULTS: One hundred seventy-four participants used aspirin. Aspirin use increased with 10-year CHD risk, from 2.6% in persons with risk <6% (low risk) to 9% in those with risk 6-20% (intermediate risk, p=0.001), but no adults with risk >or=20% used aspirin. Participants with cardiovascular risk factors were more likely to use aspirin. However, 1.9% adults with risk <6% and no diabetes used aspirin. Using a population perspective, a more appropriate aspirin use would reduce up to 2,348/24,310 CHD deaths expected over 10 years in Switzerland, and avoid about 700 gastrointestinal bleedings and hemorrhagic strokes among those not eligible. CONCLUSION: Individuals at intermediate CHD risk and diabetics are more likely to take aspirin, but there are significant opportunities for improvement. The underuse of aspirin for those at risk coexists with an overuse among those at low risk.
Authors: Tinh-Hai Collet; Sophie Salamin; Lukas Zimmerli; Eve A Kerr; Carole Clair; Michel Picard-Kossovsky; Eric Vittinghoff; Edouard Battegay; Jean-Michel Gaspoz; Jacques Cornuz; Nicolas Rodondi Journal: J Gen Intern Med Date: 2011-03-22 Impact factor: 5.128
Authors: Wen-Yi Huang; Sarah E Daugherty; Meredith S Shiels; Mark P Purdue; Neal D Freedman; Christian C Abnet; Albert R Hollenbeck; Richard B Hayes; Debra T Silverman; Sonja I Berndt Journal: Epidemiology Date: 2018-01 Impact factor: 4.822
Authors: Karen Kapur; Toby Johnson; Noam D Beckmann; Joban Sehmi; Toshiko Tanaka; Zoltán Kutalik; Unnur Styrkarsdottir; Weihua Zhang; Diana Marek; Daniel F Gudbjartsson; Yuri Milaneschi; Hilma Holm; Angelo Diiorio; Dawn Waterworth; Yun Li; Andrew B Singleton; Unnur S Bjornsdottir; Gunnar Sigurdsson; Dena G Hernandez; Ranil Desilva; Paul Elliott; Gudmundur I Eyjolfsson; Jack M Guralnik; James Scott; Unnur Thorsteinsdottir; Stefania Bandinelli; John Chambers; Kari Stefansson; Gérard Waeber; Luigi Ferrucci; Jaspal S Kooner; Vincent Mooser; Peter Vollenweider; Jacques S Beckmann; Murielle Bochud; Sven Bergmann Journal: PLoS Genet Date: 2010-07-22 Impact factor: 5.917
Authors: Russell V Luepker; Niki C Oldenburg; Jeffrey R Misialek; Jeremy R Van't Hof; John R Finnegan; Milton Eder; Sue Duval Journal: Am J Prev Med Date: 2021-02-03 Impact factor: 5.043
Authors: Paul Sebo; Hubert Maisonneuve; Bernard Cerutti; Jean-Pascal Fournier; Nicolas Senn; Cédric Rat; Dagmar M Haller Journal: PLoS One Date: 2017-09-05 Impact factor: 3.240
Authors: Sultan Alghadeer; Abdulrahman M Alwhaibi; Abdulaziz Alhossan; Salmeen D Babelghaith; Abdullah M Mubarak; Sana Samreen; Nouf N Alameel; Noura N Aljabali; Mohamed N Al-Arifi Journal: Saudi Pharm J Date: 2022-02-11 Impact factor: 4.562